Patent 9624175 was granted and assigned to FORMA Therapeutics on April, 2017 by the United States Patent and Trademark Office.
The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: